KYTX Kyverna Therapeutics, Inc.
Company Analysis
Latest News
🟢 Kyverna Therapeutics is trading 5% up in pre-market with catalyst unconfirmed
Kyverna Therapeutics is trading at $6.51, up 5.34%, with no clear company-specific announcement dated October 9 explaining the pre-market gain. - On October...
🔴 Kyverna Therapeutics is trading 9% down in pre-market with no company explanation identified
Kyverna Therapeutics is trading 9.02% lower at $5.75 in pre-market on October 6, 2026; no October 6 company announcement explaining the decline was...
🔴 Kyverna Therapeutics is trading 5% down, as biotech-sector weakness may be contributing
Kyverna Therapeutics is trading 5.21% lower at $6.18, with biotech-sector weakness a possible contributor. - No new company-specific announcement explaining...
🔴 Kyverna Therapeutics is trading 5.7% down in pre-market amid biotech-sector pressure
Kyverna Therapeutics is trading at $6.15, down 5.67%, with biotech-sector weakness potentially contributing to the decline. - Biotech was 2.01% lower...
🔴 Kyverna Therapeutics is trading 8.8% down in pre-market with no fresh company-specific announcement identified
Kyverna Therapeutics is trading 8.8% down at $6.20 in pre-market, with no fresh company-specific announcement identified to explain the decline. - Recent...
🔴 Kyverna Therapeutics is trading 5% down today
Kyverna Therapeutics is trading at $6.64, down 5.01%, despite reporting positive one-year miv-cel data on September 24; its company-specific release contained...
🔴 Kyverna Therapeutics is trading 5.4% down today as Treasury yields reach multi-year highs
Kyverna Therapeutics is trading at $6.69, down 5.4%, as biotechnology and major indexes fall amid multi-year-high Treasury yields, pressuring rate-sensitive...
Kyverna's One-Year Data Clears a Key Hurdle, but Can a $500 Million Biotech Win the Race to Make CAR-T Work for Autoimmune Disease?
Shares of Kyverna Therapeutics surged 13.1% to $8.00 Wednesday morning after the company reported that its lead cell therapy produced durable responses with a...
🟢 Kyverna Therapeutics is trading 13% up in pre-market after durable one-year miv-cel responses
Kyverna Therapeutics is trading 13% higher at $8.00 after reporting positive one-year miv-cel data in stiff person syndrome and longer-term generalized...
Kyverna Reports Positive One-Year Miv-cel Data in Stiff Person Syndrome and gMG Trials
Kyverna Therapeutics (KYTX) announced positive one-year clinical trial data for its CAR T-cell therapy, miv-cel, in patients with stiff person syndrome (SPS)...
🟢 Kyverna Therapeutics is trading 6% up in pre-market after positive KYSA-8 and KYSA-6 data
Kyverna Therapeutics is trading at $7.50, up 6.08%, after announcing positive one-year KYSA-8 data in stiff person syndrome and longer-term KYSA-6 results in...
🟢 Kyverna Therapeutics is trading 7.5% up in after-hours trading with no confirmed catalyst
Kyverna Therapeutics is trading 7.5% higher at $7.60 after-hours, with no confirmed explanation for the rebound. - It closed at $7.07 on September 23, 2026;...
🔴 Kyverna Therapeutics is trading 5% down today as oil and Treasury yields renew inflation concerns
Kyverna Therapeutics is trading 5.13% down now at $7.12, with the decline best attributed to global risk-off sentiment after broader market weakness emerged on...
🟢 Kyverna Therapeutics rises 5.1% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🔴 Kyverna Therapeutics falls 5.0% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Kyverna Therapeutics is trading 7.2% up in pre-market amid Wells Fargo disclosures on miv-cel progress
Kyverna Therapeutics is trading 7.2% up in pre-market at $8.19 amid September 9, 2026 disclosures at the Wells Fargo Healthcare Conference highlighting...